News >

Alpelisib Active in PIK3CA-Altered Solid Tumors

Jason Harris
Published: Thursday, Feb 08, 2018

Dr Jose Baselga

José Baselga, MD, PhD
Alpelisib (BYL719) induced a disease control rate (DCR) of 58.2% in patients with advanced solid tumors, according to results from a phase Ia study published in the Journal of Clinical Oncology.

Treatment with the oral PIK3CA selective inhibitor led to a stable disease rate of 52.2%. Thirteen (9.7%) patients maintained stable disease for more than 24 weeks.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Real-World Evidence to Inform Treatment and Management of ER+ Metastatic Breast CancerDec 31, 20191.0
Medical Crossfire®: A Critical Assessment of Current and Emerging Data Sets to Move Treatment of Triple-Negative Breast Cancer ForwardJan 31, 20201.0
Publication Bottom Border
Border Publication